Somatostatin receptor SPECT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue SUPPL.1, 2012, Pages

  Pepe, Giovanna ^a   Moncayo, Roy ^b   Bombardieri, Emilio ^c   Chiti, Arturo ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gastroenteropancreatic (GEP) tumours; Neuroendocrine tumours (NET); Peptide receptor radionuclide therapy (PRRT); Single photon emission computed tomography (SPECT); Somatostatin; Somatostatin receptor scintigraphy (SRS)

Indexed keywords

ANGIOPEPTIN; DEMOTATE TC 99M; DEPREOTIDE TC 99M; DOTA D PHE 1 TYR 3 OCTREOTIDE IN 111; DOTA LANREOTIDE IN 111; DOTA TATE LU 177; DOTA TATE Y 90; DOTALAN Y 90; DOTANOC ATE IN 111; DOTANOC IN 111; DTPA D PHE OCTREOTIDE IN 111; OCTREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TYR 3 OCTREOTATE I 123; TYR 3 OCTREOTIDE I 123; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PEPTIDE; SOMATOSTATIN;

HUMAN; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL; CARCINOID; DIGESTIVE SYSTEM TUMOR; FEMALE; HYPOPHYSIS TUMOR; ISOTOPE LABELING; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; NEOPLASM; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SCINTISCANNING;

CARCINOID TUMOR; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; HUMANS; ISOTOPE LABELING; LUNG NEOPLASMS; MALE; NEOPLASMS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PARAGANGLIOMA; PEPTIDES; PHEOCHROMOCYTOMA; PITUITARY NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SMALL CELL LUNG CARCINOMA; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84863807080     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2019-2     Document Type: Review

References (112)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9.
2. Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984;2:782-4.
3. Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994;198:605-12.
4. Pangerl T, Peck-Radosavljevic M, Kaserer K, Niederle B, Gangl A, Virgolini I. Somatostatin (SST) and VIP receptor subtype gene expression in human tumors. Eur J Nucl Med 1997;24:995A.
5. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
6. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36(3):228-47.
7. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radiolabeled analogue of somatostatin. Lancet 1989;1:242-5.
8. Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994;54:690-700.
9. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-9.
10. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol 2004;15(4):275-92.
11. de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002;14:53-7.
12. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-9.
13. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
14. Raynor K, Lucki I, Reisine T. Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats. J Pharmacol Exp Ther 1993;265:67-73.
15. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-82.
16. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995;16:86-8.
17. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Drug therapy: octreotide. N Engl J Med 1996;334:246-54.
18. Smith-Jones P, Bischof C, Leimer M, Gludovac D, Angelberger P, Pangerl T, et al. "MAURITIUS" a novel somatostatin analog for tumor diagnosis and therapy. J Nucl Med 1998;39:223A.
19. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33:652-8.
20. Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med 2000;27(6):628-37.
21. Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318-25.
22. Kainz H, Bale R, Donnemiller E, Gabriel M, Kovacs P, Decristoforo C, et al. Image fusion analysis of (99m)Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging 2003;30:1155-9.
23. Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Herder WW, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57:57-61.
24. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-47.
25. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
26. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11:1136-45.
27. De Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41.
28. Stahl A, Meisetschläger G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. Eur J Nucl Med Mol Imaging 2006;33(1):45-52.
29. Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas D, et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29(6):742-53.
30. Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, et al. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate. Eur J Nucl Med Mol Imaging 2006;33(7):831-40.
31. Decristoforo C, Maina T, Nock B, Gabriel M, Cordopatis P, Moncayo R. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging 2003;30:1211-9.
32. Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T. MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. J Nucl Med 2005;46:1889-97.
33. Gabriel M, Decristoforo C, Wöll E, Eisterer W, Nock B, Maina T, et al. [99mTc]Demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. Cancer Biother Radiopharm 2011;26(5):557-63.
34. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
35. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med 2002;32:92-6.
36. Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, et al. Detection of neuroendocrine tumors: (99m)Tc-P829 scintigraphy compared with (111)In-pentetreotide scintigraphy. J Nucl Med 2002;43:889-95.
37. Bogatzky J, Guhlke S, Bender H, Sartor J, Knapp FF, Biersack HJ. Receptor binding studies with rhenium-RC160, a directly-labeled somatostatin analog, with membranes of the colon cancer cell line HT 29, CHO cells and ovary carcinoma cell line EFO-21. Eur J Nucl Med 1997;24:1059A.
38. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bischof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441-8.
39. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1998;28:3. Oxford: Pergamon.
40. ICRP Publication 62. Radiological protection in biomedical research. Ann ICRP 1991;22:3. Oxford: Pergamon.
41. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1987;18:1-4. Oxford: Pergamon.
42. ICRP Publication 106. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. Approved by the Commission in October 2007. Ann ICRP 2008;38(1-2):1-197.
43. Steffen IG, Mehl S, Heuck F, Elgeti F, Furth C, Amthauer H, et al. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Clin Nucl Med 2009;34(12):869-73.
44. Hillel PG, van Beek EJ, Taylor C, Lorenz E, Bax ND, Prakash V, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 2006;61(7):579-87.
45. Ruf J, Steffen I, Mehl S, Rosner C, Denecke T, Pape UF, et al. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT. Nucl Med Commun 2007;28(10):782-8.
46. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, et al. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 2005;32:1440-51.
47. Jacobsson H, Bremmer S, Larsson SA. Visualisation of the normal adrenals at SPET examination with 111In-pentetreotide. Eur J Nucl Med Mol Imaging 2003;30:1169-72.
48. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32(2):84-91.
49. Gibril E, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:539-53.
50. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003;59:565-73.
51. Moreira AP, Duarte LH, Vieira F, João F, Lima JP. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy. Rev Esp Med Nucl 2005;24:14-8.
52. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008;52:323-33.
53. Briganti V, Sestini R, Orlando C, Bernini G, La Caya G, Tamburini A, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3:2385-91.
54. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJM, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73.
55. Kwekkeboom DJ, de Herder WW, Krenning EP. Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999;22:80-8.
56. Duet M, Mundler O, Azjenberg C, Berolatti B, Chedin P, Duranteau L, et al. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur J Nucl Med 1994;21:647-50.
57. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in neuroendocrine gastroenteropancreatic tumours. Q J Nucl Med 2000;44:42-9.
58. Briganti V, Matteini M, Ferri P, Vaggelli L, Castagnoli A, Pieroni C. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors. Cancer Biother Radiopharm 2001;16:515-24.
59. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004;48:150-63.
60. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In: Freeman LM, editor. Nuclear medicine annual. New York: Lippincott Williams & Wilkins; 1995. p. 1-50.
61. Westlin J, Janson ET, Arnberg H, Ahlström H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Acta Oncol 1993;32:783-6.
62. Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996;39:562-8.
63. Schillaci O, Massa R, Scopinaro F. 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 2000;41:459-62.
64. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with OctreoScan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005;152:757-67.
65. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003;88:5353-60.
66. Baldelli R, Ettorre G, Vennarecci G, Pasimeni G, Carboni F, Lorusso R, et al. Malignant insulinoma presenting as metastatic liver tumor. Case report and review of the literature. J Exp Clin Cancer Res 2007;26:603-7.
67. de Geus-Oei LF, Oei HY, Hennemann G, Krenning EP. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002;29:768-74.
68. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224-7.
69. Bombardieri E, Crippa F, Cataldo I, Chiti A, Seregni E, Soresi E, et al. Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy. Eur J Cancer 1995;31A:184-8.
70. O'Byrne KJ, Ennis JT, Freyne PJ, Clancy LJ, Prichard JS, Carney DN. Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 1994;69:762-6.
71. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;21:1106-13.
72. Kirsch CM, von Pawel J, Grau I, Tatsch K. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 1994;21:1318-25.
73. Maini CL, Tofani A, Venturo I, Pigorini F, Sciuto R, Semprebene A, et al. Somatostatin receptor imaging in small cell lung cancer using 111In-DTPA-octreotide: a preliminary study. Nucl Med Commun 1993;14:962-8.
74. Leitha T, Meghdadi S, Studnicka M, Wolzt M, Marosi C, Angelberger P, et al. The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 1993;34:1397-402.
75. Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-8.
76. Cryer PE. The adrenal medullae. In: Wyngaarden JB, Smith LH, Bennet JC, editors. Cecil textbook of medicine. 19th ed. Philadelphia: Saunders; 1992. p. 1390-4.
77. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
78. Hoefnagel CA, Lewington VJ. MIBG therapy. In: Ell PJ, Gambhir SS, editors. Nuclear medicine in clinical diagnosis and treatment, Vol. 1. New York: Churchill Livingstone; 2004. p. 445-557.
79. DeLellis RA. Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features. Lab Invest 1995;72:494-502.
80. Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg 2000;122(3):358-62.
81. Kwekkeboom DJ, van Urk H, Pauw KH, Lamberts SW, Kooij PP, Hoogma RP, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993;34:873-8.
82. Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, et al. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol 1996;23(4):503-7.
83. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912-6.
84. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-7.
85. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008;26(6):963-70.
86. Zimmer T, Ziegler K, Bäder M, Fett U, Hamm B, Riecken O, et al. Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Gut 1994;35:471-5.
87. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, et al. Localization of neuroendocrine tumours with [111In]DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 1998;91(4):295-301.
88. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996;125:26-34.
89. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25:1396-403.
90. Schillaci O. Functional-anatomical image fusion in neuroendocrine tumors. Cancer Biother Radiopharm 2004;19:129-34.
91. Moncayo R. Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis. EJNMMI Res 2011;1:9.
92. de Kerviler E, Cadiot G, Lebtahi R, Faraggi M, Le Guludec D, Mignon M. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. Eur J Nucl Med 1994;21:1191-7.
93. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-8.
94. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20:283-92.
95. Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjälling M, Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994;81:1144-9.
96. Kälkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers. Cancer Res 1995;55 Suppl 23:5801s-4s.
97. Telischi FF, Bustillo A, Whiteman ML, Serafini AN, Reisberg MJ, Gomez-Marin O, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg 2000;122:358-62.
98. Duet M, Sauvaget E, Pételle B, Rizzo N, Guichard JP, Wassef M, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003;44:1767-74.
99. Haldemann AR, Rösler H, Barth A, Waser B, Geiger L, Godoy N, et al. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J Nucl Med 1995;36:403-10.
100. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998;25:675-86.
101. Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994;21:497-502.
102. Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med 1998;25:1284-92.
103. Postema PTE, Krenning EP, Wijngaarde R, Kooy PP, Oei HY, van den Bosch WA, et al. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab 1994;79:1845-51.
104. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995;42:571-80.
105. Tisell LE, Ahlman H, Wängberg B, Hansson G, Mölne J, Nilsson O, et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997;84:543-7.
106. Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998;25:1277-83.
107. Postema PTE, De Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996;57:36-7.
108. Haslinghuis LM, Krenning EP, de Herder WW, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 2001;24:415-22.
109. van Eijck CH, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994;343:640-3.
110. Lugtenburg PJ, Löwenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J Nucl Med 2001;42:222-9.
111. Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified. Br J Haematol 2001;112:936-44.
112. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.